Research progress of FLT3 inhibitors and drug resistance mechanisms in acute myeloid leukemia
The FMS-like tyrosine kinase 3(FLT3)gene mutation is the most common genetic muta-tion in acute myeloid leukemia(AML)and is associ-ated with poor prognosis.Various targeted inhibi-tors have been developed for FLT3 mutations and have shown promising clinical efficacy.However,the emergence of resistance poses new challenges for targeted therapy in AML.This article provides an overview of the pathological and prognostic role of FLT3 mutations in AML,the current research progress on commonly used FLT3 inhibitors(type Ⅰand type Ⅱ),the mechanisms of FLT3 inhibitor resis-tance,and strategies for overcoming resistance.
国家科技期刊平台
NSTL
万方数据
维普
